Abstract
Background and aims: Osteoporosis is a chronic condition requiring long-term treatment, for which compliance is not easy to achieve. 70 mg of alendronate once weekly (alendronate OW) provides equivalent efficacy to treatment with 10 mg of alendronate once a day (alendronate OD); however, there are relatively few data regarding patient and physician preferences for once-weekly vs daily dosing. The aim of this study was to measure compliance, convenience, tolerance and relative preference of alendronate OW treatment among post-menopausal women with osteoporosis and physician satisfaction, compared with previous treatment with alendronate OD. Methods: This open-label, prospective multi-center trial was conducted at 14 hospitals and 150 primary-care community clinics in Israel. Post-menopausal osteoporotic women (n=3710), who had been treated for at least 1 month with alendronate OD during the preceding year, were treated with alendronate OW for 12 weeks. Convenience, satisfaction, tolerance and relative preference of alendronate OW during the trial, compared with past experience with alendronate OD, were recorded. Results: Overall, 96% of the patients preferred the alendronate OW regimen to the 10-mg daily dosage. Nearly all (98%) the patients who completed 12 weeks of treatment, including 77% of patients who had previously discontinued daily treatment due to intolerance, were willing to continue the alendronate OW regimen. Patient-reported compliance with dosing instructions was over 98%. Alendronate OW was well tolerated; only 2.8% of patients discontinued, due to adverse events. Physicians were highly satisfied with the once-weekly dosing regimen, and recommended continued treatment with alendronate OW for 99% of the patients. Conclusions: The majority of post-menopausal women with osteoporosis, including those who were previously intolerant to alendronate OD, preferred alendronate OW to the once-daily dosing regimen. It is important to consider patient preference when selecting the appropriate treatment for osteoporosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zuckerman JD. Hip fracture. N Engl J Med 1996; 334: 1519–25.
Ray N, Chan JK, Thamer M, Melton LJ III. Medical expenditure for the treatment of osteoporotic fractures in the United States in 1995. J Bone Miner Res 1997; 12: 24–35.
Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001; 12: 356–61.
Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D, for the European Foundation for Osteoporosis and Bone Disease. Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 1997; 7: 390–406.
Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, for the Alendronate Phase III Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437–43.
Black DM, Cummings SR, Karpf DB, et al., for the Fracture Intervention Trial Research Group. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41.
Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002; 77: 1044–52.
Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1998; 48: 1978–88.
Wright EC. Non-compliance: or how many aunts has Matilda? Lancet 1993; 342: 909–13.
Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–4.
Doice CR. Patient cooperation and the sensitivity of clinical trials. J Chronic Dis 1962; 15: 1025–76.
Gordis L, Markowitz M, Lilienfeld M. Why patients don’t follow medical advice: a study of children on long-term antistreptococcal prophylaxis. J Pediatr 1963; 75: 957–68.
ZuWallack RL, Rosen JP, Cohen L, et al. The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. J Allergy Clin Immunol 1997; 99: 278–85.
Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Quellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–7.
Bockowski JA, Zeichner A. Medication compliance and the elderly. Clin Gerontol 1985; 4: 3–15.
Stuart B, Coulson NE. Dynamic aspects of prescription drug use in an elderly population. Health Res 1993; 28: 237–64.
Luscher TF, Vetter H, Siegenthaler W, Vetter W. Compliance in hypertension: facts and concepts. J Hypertension 1985; 3(Suppl 1): 3–9.
Paes AHP, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997; 20: 1512–7.
Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995; 36: 1111–7.
Ridwan E, Schultink W, Dillon D, Gross R. Effects of weekly iron supplementation on pregnant Indonesian women are similar to those of daily supplementation. Am J Clin Nutr 1996; 63: 884–90.
Schnitzer T, Bone HG, Crepaldi G, et al., for the Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000; 12: 1–12.
Greenspan SL, Bone HG 3rd, Schnitzer TJ, et al., for the Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17: 1988–96.
Peter CP, Handt LK, Smith SM. Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 1998; 43: 1998–2002.
Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002; 24: 1871–86.
Kendler D, Wai Chee Rung A, El-Hajj Fuleihan G, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004; 48: 243–51.
Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000; 22: 1433–42.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
For complete list of investigators, see Appendix A.
Rights and permissions
About this article
Cite this article
Weiss, M., Vered, I., Foldes, A.J. et al. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 17, 143–149 (2005). https://doi.org/10.1007/BF03324587
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03324587